- Home
- RIGL vs RYAM Comparison
RIGL vs RYAM Comparison
Compare RIGL & RYAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- RYAM
- Stock Information
- Founded
- RIGL 1996
- RYAM 1926
- Country
- RIGL United States
- RYAM United States
- Employees
- RIGL N/A
- RYAM N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- RYAM Paper
- Sector
- RIGL Health Care
- RYAM Basic Materials
- Exchange
- RIGL Nasdaq
- RYAM Nasdaq
- Market Cap
- RIGL 298.0M
- RYAM 312.4M
- IPO Year
- RIGL 2000
- RYAM N/A
- Fundamental
- Price
- RIGL $17.28
- RYAM $4.28
- Analyst Decision
- RIGL Buy
- RYAM Buy
- Analyst Count
- RIGL 5
- RYAM 1
- Target Price
- RIGL $36.80
- RYAM $11.00
- AVG Volume (30 Days)
- RIGL 222.1K
- RYAM 599.7K
- Earning Date
- RIGL 05-06-2025
- RYAM 05-06-2025
- Dividend Yield
- RIGL N/A
- RYAM N/A
- EPS Growth
- RIGL N/A
- RYAM N/A
- EPS
- RIGL 0.99
- RYAM N/A
- Revenue
- RIGL $179,278,000.00
- RYAM $1,630,308,000.00
- Revenue This Year
- RIGL $12.53
- RYAM $1.51
- Revenue Next Year
- RIGL $15.68
- RYAM $4.47
- P/E Ratio
- RIGL $17.36
- RYAM N/A
- Revenue Growth
- RIGL 54.71
- RYAM N/A
- 52 Week Low
- RIGL $7.48
- RYAM $3.72
- 52 Week High
- RIGL $29.82
- RYAM $10.28
- Technical
- Relative Strength Index (RSI)
- RIGL 44.84
- RYAM 29.29
- Support Level
- RIGL $16.05
- RYAM $4.05
- Resistance Level
- RIGL $17.52
- RYAM $5.25
- Average True Range (ATR)
- RIGL 1.26
- RYAM 0.31
- MACD
- RIGL 0.10
- RYAM -0.03
- Stochastic Oscillator
- RIGL 63.57
- RYAM 13.29
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About RYAM Rayonier Advanced Materials Inc.
Rayonier Advanced Materials Inc is engaged in the production of cellulose specialties, a natural polymer used in the manufacturing of various specialty chemical products, including liquid crystal displays, filters, textiles and performance additives for pharmaceutical, food and other industrial applications. The company's products are used in a variety of applications, including cigarette filters, liquid crystal displays, paints, pharmaceuticals, and food. The company operates in the reportable segments of High Purity Cellulose, Paperboard, and High-Yield Pulp. The key revenue is derived from the High Purity Cellulose segment. Geographically, it derives a majority of its revenue from the United States.